Salarius gets additional Nasdaq extension to late July 2025 for equity standard compliance

Decoy Therapeutics Inc.

Nasdaq Hearings Panel extended deadline to regain Equity Standard compliance to late July 2025.
Minimum Bid Price Requirement must be met by early August 2025.
On Jan 13, 2025, Salarius announced a merger agreement with Decoy Therapeutics; combined company to be named Decoy Therapeutics.
Failure to meet milestones could trigger delisting; previous deadline for equity standard was early July 2025.
Merger closing conditions remain; Decoy's CEO Rick Pierce will lead combined company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.